BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms 2021;9:523. [PMID: 33806386 DOI: 10.3390/microorganisms9030523] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
Number Citing Articles
1 Nagesh CP. The "black fungus" through a gray lens: Imaging COVID-19-associated mucormycosis. Indian J Ophthalmol 2021;69:1648-9. [PMID: 34146001 DOI: 10.4103/ijo.IJO_1506_21] [Reference Citation Analysis]
2 Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, Sharma M, Sachdev M, Grover AK, Surve A, Budharapu A, Ramadhin AK, Tripathi AK, Gupta A, Bhargava A, Sahu A, Khairnar A, Kochar A, Madhavani A, Shrivastava AK, Desai AK, Paul A, Ayyar A, Bhatnagar A, Singhal A, Nikose AS, Bhargava A, Tenagi AL, Kamble A, Nariani A, Patel B, Kashyap B, Dhawan B, Vohra B, Mandke C, Thrishulamurthy C, Sambare C, Sarkar D, Mankad DS, Maheshwari D, Lalwani D, Kanani D, Patel D, Manjandavida FP, Godhani F, Agarwal GA, Ravulaparthi G, Shilpa GV, Deshpande G, Thakkar H, Shah H, Ojha HR, Jani H, Gontia J, Mishrikotkar JP, Likhari K, Prajapati K, Porwal K, Koka K, Dharawat KS, Ramamurthy LB, Bhattacharyya M, Saini M, Christy MC, Das M, Hada M, Panchal M, Pandharpurkar M, Ali MO, Porwal M, Gangashetappa N, Mehrotra N, Bijlani N, Gajendragadkar N, Nagarkar NM, Modi P, Rewri P, Sao P, Patil PS, Giri P, Kapadia P, Yadav P, Bhagat P, Parekh R, Dyaberi R, Chauhan RS, Kaur R, Duvesh RK, Murthy R, Dandu RV, Kathiara R, Beri R, Pandit R, Rani RH, Gupta R, Pherwani R, Sapkal R, Mehta R, Tadepalli S, Fatima S, Karmarkar S, Patil SS, Shah S, Shah S, Shah S, Dubey S, Gandhi S, Kanakpur S, Mohan S, Bhomaj S, Kerkar S, Jariwala S, Sahu S, Tara S, Maru SK, Jhavar S, Sharma S, Gupta S, Kumari S, Das S, Menon S, Burkule S, Nisar SP, Kaliaperumal S, Rao S, Pakrasi S, Rathod S, Biradar SG, Kumar S, Dutt S, Bansal S, Ravani SA, Lohiya S, Ali Rizvi SW, Gokhale T, Lahane TP, Vukkadala T, Grover T, Bhesaniya T, Chawla U, Singh U, Une VL, Nandedkar V, Subramaniam V, Eswaran V, Chaudhry VN, Rangarajan V, Dehane V, Sahasrabudhe VM, Sowjanya Y, Tupkary Y, Phadke Y; members of the Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) Study Group. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol 2021;69:1670-92. [PMID: 34156034 DOI: 10.4103/ijo.IJO_1565_21] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
3 Zolin GVS, Fonseca FHD, Zambom CR, Garrido SS. Histatin 5 Metallopeptides and Their Potential against Candida albicans Pathogenicity and Drug Resistance. Biomolecules 2021;11:1209. [PMID: 34439875 DOI: 10.3390/biom11081209] [Reference Citation Analysis]
4 Prakash H, Skiada A, Paul RA, Chakrabarti A, Rudramurthy SM. Connecting the Dots: Interplay of Pathogenic Mechanisms between COVID-19 Disease and Mucormycosis. J Fungi (Basel) 2021;7:616. [PMID: 34436155 DOI: 10.3390/jof7080616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nambiar M, Varma SR, Damdoum M. Post-Covid alliance-mucormycosis, a fatal sequel to the pandemic in India. Saudi J Biol Sci 2021. [PMID: 34305427 DOI: 10.1016/j.sjbs.2021.07.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Hallur V, Prakash H, Sable M, Preetam C, Purushotham P, Senapati R, Shankarnarayan SA, Bag ND, Rudramurthy SM. Cunninghamella arunalokei a New Species of Cunninghamella from India Causing Disease in an Immunocompetent Individual. J Fungi (Basel) 2021;7:670. [PMID: 34436209 DOI: 10.3390/jof7080670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Vinay K, Rudramurthy SM, Dogra S. Emergence of Mucormycosis during COVID-19 Pandemic and Dermatological Manifestations. Indian Dermatol Online J 2021;12:493-6. [PMID: 34430451 DOI: 10.4103/idoj.idoj_406_21] [Reference Citation Analysis]
8 Rudramurthy SM, Hoenigl M, Meis JF, Cornely OA, Muthu V, Gangneux JP, Perfect J, Chakrabarti A; ECMM and ISHAM. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 2021;64:1028-37. [PMID: 34133816 DOI: 10.1111/myc.13335] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
9 Gupta S, Ahuja P. Risk Factors for Procurence of Mucormycosis and its Manifestations Post Covid-19: a Single Arm Retrospective Unicentric Clinical Study. Indian J Otolaryngol Head Neck Surg 2021;:1-8. [PMID: 34567997 DOI: 10.1007/s12070-021-02825-0] [Reference Citation Analysis]
10 Diwakar J, Samaddar A, Konar SK, Bhat MD, Manuel E, Hb V, Bn N, Parveen A, Hajira SN, Srinivas D, S N. First report of COVID-19-associated rhino-orbito-cerebral mucormycosis in pediatric patients with type 1 diabetes mellitus. J Mycol Med 2021;31:101203. [PMID: 34517273 DOI: 10.1016/j.mycmed.2021.101203] [Reference Citation Analysis]
11 Sarda R, Swain S, Ray A, Wig N. COVID-19 associated Mucormycosis: An epidemic within a pandemic. QJM 2021:hcab165. [PMID: 34109406 DOI: 10.1093/qjmed/hcab165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Vuorio A, Kovanen PT. Mucormycosis and glucose-regulated protein 78 in COVID-19: Amenable to statin treatment? J Intern Med 2021. [PMID: 34133038 DOI: 10.1111/joim.13347] [Reference Citation Analysis]
13 Singh G, Vishnu VY. Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era. Nat Rev Neurol 2021;17:657-8. [PMID: 34480144 DOI: 10.1038/s41582-021-00560-2] [Reference Citation Analysis]
14 Buil JB, van Zanten ARH, Bentvelsen RG, Rijpstra TA, Goorhuis B, van der Voort S, Wammes LJ, Janson JA, Melchers M, Heusinkveld M, Melchers WJG, Kuijper EJ, Verweij PE. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Euro Surveill 2021;26. [PMID: 34114540 DOI: 10.2807/1560-7917.ES.2021.26.23.2100510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Ezeokoli OT, Gcilitshana O, Pohl CH. Risk Factors for Fungal Co-Infections in Critically Ill COVID-19 Patients, with a Focus on Immunosuppressants. J Fungi (Basel) 2021;7:545. [PMID: 34356924 DOI: 10.3390/jof7070545] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Randhawa G, Hagaman S, Pourabdollah Tootkaboni M, Kundal SV, Oli S, Alrassi J, Schild SD, Abu-Ghanem S, Brejt S. A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone. Am J Case Rep 2021;22:e932129. [PMID: 34310559 DOI: 10.12659/AJCR.932129] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Agarwal P, Sharma D. Total eyelid complex sparing orbital exenteration for mucormycosis. Trop Doct 2021;:494755211041865. [PMID: 34482784 DOI: 10.1177/00494755211041865] [Reference Citation Analysis]
18 Malhotra HS, Gupta P, Mehrotra D, Dandu H, Kohli N, Verma V, Kaur A, Kumar N, Prabhu V, Singh MK, Jaiswal R, Mishra B, Ojha BK, Bhardwaj ND, Atam V, Puri B. COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee). J Oral Biol Craniofac Res 2021;11:569-80. [PMID: 34395187 DOI: 10.1016/j.jobcr.2021.08.001] [Reference Citation Analysis]
19 Nambiar M, Varma SR, Jaber M, Sreelatha SV, Thomas B, Nair AS. Mycotic infections - mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association. J Oral Microbiol 2021;13:1967699. [PMID: 34527182 DOI: 10.1080/20002297.2021.1967699] [Reference Citation Analysis]
20 Raghav A, Ali SG, Jeong GB, Gautam KA, Banday S, Mateen QN, Tripathi P, Giri R, Agarwal S, Singh M, Khan HM. Newer Horizon of Mesenchymal Stem Cell-Based Therapy in the Management of SARS-CoV-2-Associated Mucormycosis: A Safe Hope for Future Medicine. Front Microbiol 2021;12:738983. [PMID: 34707590 DOI: 10.3389/fmicb.2021.738983] [Reference Citation Analysis]
21 Banerjee I, Robinson J, Asim M, Sathian B, Banerjee I. Mucormycosis and COVID-19 an epidemic in a pandemic? Nepal J Epidemiol 2021;11:1034-9. [PMID: 34290893 DOI: 10.3126/nje.v11i2.37342] [Reference Citation Analysis]
22 Dasukil S, Boyina KK, Sarkar S, Hallur V, Nayak A, Mishra AK, Aswathi KV, Preetam C, Parida PK. Management of Covid Associated Mucormycosis of Mandible: A Mountain Beneath a Molehill-A Lesson Learnt. Indian J Otolaryngol Head Neck Surg 2021;:1-4. [PMID: 34667749 DOI: 10.1007/s12070-021-02925-x] [Reference Citation Analysis]
23 Mehta R, Nagarkar NM, Jindal A, Rao KN, Nidhin SB, Arora RD, Sharma A, Wankhede A, Satpute S, Chakravarty S, Agrawal NK, Pranita, Kannauje P, Behera A, Thangaraju P. Multidisciplinary Management of COVID-Associated Mucormycosis Syndemic in India. Indian J Surg 2021;:1-9. [PMID: 34642558 DOI: 10.1007/s12262-021-03134-0] [Reference Citation Analysis]
24 Al-Tawfiq JA, Alhumaid S, Alshukairi AN, Temsah MH, Barry M, Al Mutair A, Rabaan AA, Al-Omari A, Tirupathi R, AlQahtani M, AlBahrani S, Dhama K. COVID-19 and mucormycosis superinfection: the perfect storm. Infection 2021. [PMID: 34302291 DOI: 10.1007/s15010-021-01670-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Thakar A, Lal D. "Black fungus": a perspective on the coronavirus disease 2019 (COVID-19)-associated rhino-orbital mucormycosis epidemic in India. Int Forum Allergy Rhinol 2021;11:1278-9. [PMID: 34185968 DOI: 10.1002/alr.22855] [Cited by in F6Publishing: 1] [Reference Citation Analysis]